Results 31 to 40 of about 299,195 (309)

Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer [PDF]

, 2014
Copyright: © 2014 Li, Symonds, Miao, Sanderson and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Abraham, Ahmadzadeh, Akbar, Anderson, Baine, Barber, Baur, Belkaid, Bensinger, Bergmann, Berzofsky, Blackburn, Brooks, Brooks, Brooks, Colonna, Das, Day, Duraiswamy, Ejrnaes, Frebel, Geijtenbeek, Guidotti, Ha, Jerome, Jung, Kasprowicz, Kaufmann, Kim, Klein, Kroemer, Kroy, Larsson, Liu, Lu, Maizels, Malek, Matsuzaki, Mier, Mumprecht, Nandedkar, Nurieva, Nurieva, Ramsay, Schietinger, Schwartz, Sofra, Soldaini, Steinman, Trautmann, Vezys, Waggoner, Wedemeyer, Wilson, Yi, Zhou   +55 more
core   +2 more sources

Post-Vaccination and Post-Infection Immunity to the Hepatitis B Virus and Circulation of Immune-Escape Variants in the Russian Federation 20 Years after the Start of Mass Vaccination

Vaccines, 2023
A neonatal vaccination against the Hepatitis B virus (HBV) infection was initiated in Russia 20 years ago, with catch-up immunization for adolescents and adults under the age of 60 years launched in 2006.
Fedor A. Asadi Mobarkhan, Victor A. Manuylov, Anastasia A. Karlsen, Vera S. Kichatova, Ilya A. Potemkin, Maria A. Lopatukhina, Olga V. Isaeva, Eugeniy V. Mullin, Elena P. Mazunina, Evgeniia N. Bykonia, Denis A. Kleymenov, Liubov I. Popova, Vladimir A. Gushchin, Artem P. Tkachuk, Anna A. Saryglar, Irina E. Kravchenko, Snezhana S. Sleptsova, Victor V. Romanenko, Anna V. Kuznetsova, Sergey A. Solonin, Tatyana A. Semenenko, Mikhail I. Mikhailov, Karen K. Kyuregyan   +22 more
doaj   +1 more source

Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 Mice [PDF]

, 2013
Backgrounds: Most of the hepatitis C virus (HCV) infections elicit poor immune responses and 75% to 85% of cases become chronic; therefore, the development of an effective vaccine against HCV is of paramount importance.
Behnampour, N., Ghaemi, A., Gorzin, A.A., Gorzin, Z., Irani, S., Tabarraei, A.   +5 more
core   +2 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source

PECULIARITIES OF TREATMENT AND PREVENTION OF INFECTION CAUSED BY HEPATITIS C VIRUS. Review

Медична наука України, 2022
Relevance. The goal of the WHO Global Strategy on Hepatitis Agents, in particular hepatitis C virus, is to identify infected people early for treatment and prevention of chronic infection.
T.L. Hrydina
doaj   +1 more source

Hepatitis C virus infection and related liver disease: the quest for the best animal model [PDF]

, 2013
Hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma (HCC) making the virus the most common cause of liver failure and transplantation.
Baumert, Thomas F, Mailly, Laurent, Meuleman, Philip, Robinet, Eric, Zeisel, Mirjam   +4 more
core   +3 more sources

Viral Hepatitis in pregnancy.

European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2020
The global prevalence of viral hepatitis is very high and seems to be rising over the years. The infection can profoundly affect pregnant women causing significant maternal and perinatal morbidity and mortality with some strains much worse than others ...
V. Chilaka, J. Konje
semanticscholar   +1 more source

Identification of hepatitis a virus mimotopes by phage display, antigenicity and immunogenicity [PDF]

, 2007
A phage-displayed peptide approach was used to identify ligands mimicking antigenic determinants of hepatitis A virus (HAV) for the first time. Bacteriophages displaying HAV mimotopes were isolated from a phage-display peptide library by affinity ...
Alicia Aguilar, Altschul, Arturo Talavera, Beales, Beckmann, Bosch, Burritt, Burritt, Clark, Cohen, Collins, Cuthbert, David I. Stott, de la Cruz, Delmastro, Ela M. Perez, Emini, Enshell-Seijffers, Felici, Folgori, Folgori, Frank Camacho, Gomara, Hollinger, Hoogenboon, Irving, Lemon, Lemon, Lemon, Lemon, Lemon, Lemon, Marston, Martin, Mattioli, Nainan, Neduva, Nevis Amin, Osmany G. Larralde, Partidos, Perea, Perez, Ping, Ping, Prezzi, Raiza Martinez, Reed, Sambrook, Scholfield, Stapleton, Stapleton, Stapleton, Verdaguer, Wan, Zhang   +54 more
core   +1 more source

Community screening for hepatitis C virus infection in a low-prevalence population

BMC Public Health, 2019
Background Age cohort screening for hepatitis C virus (HCV) might be an effective strategy if the majority of undiagnosed cases are concentrated in a particular age group.
Karen K. Kyuregyan, Elena Yu. Malinnikova, Natalia V. Soboleva, Olga V. Isaeva, Anastasia A. Karlsen, Vera S. Kichatova, Ilya A. Potemkin, Elena V. Schibrik, Olga A. Gadjieva, Boris A. Bashiryan, Natalya N. Lebedeva, Igor L. Serkov, Anna Yankina, Claudio Galli, Mikhail I. Mikhailov   +14 more
doaj   +1 more source

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity

Viruses, 2021
Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030.
Felicia Schlotthauer, Joey McGregor, Heidi E Drummer   +2 more
doaj   +1 more source